Emicizumab in hemophilia A with inhibitors: clinical and economic impact of its use in a Cuban patient

Introduction: The management of a patient with severe hemophilia A inhibitors is challenge for any healthcare professional. present analysis shows the clinical and economic impact therapeutic approach in most critical Cuban Hemophilia Cohort. Objective: To evaluate implementation Emicizumab therapy first patient. Case presentation: Adult who started to use recombinant activated factor VII episodically during adolescence when he was diagnosed presence high-responding antibodies against VIII. During years that used this medication, had recorded between 95 105 bleeds annually. In 2018, presented hemoperitoneum admitted intensive care unit high doses activated, multiple transfusions packed red blood cells, other typical critically ill patient; his evolution satisfactory. He emicizumab prophylaxis 7 months after event currently on Week 133 treatment. has not further bleeding, nor reported adverse reactions biannual cost savings on-demand treatment have been US $792,509.24. Conclusions: improved patient’s quality life family. From perspective health system, case satisfactory its experience will be analyzed new patients.